Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

Lilly backs Bluetooth insulin device and app firm

Invests in San Diego-based medical device company Companion Medical

Digital pharmaLilly has invested in a company that's developing a Bluetooth-enabled insulin pen and associated smartphone app.

The firm will also sit on the board of San Diego-based medical device firm Companion Medical, which is developing advanced systems for delivery of insulin and other drugs.

Divakar Ramakrishnan, vice president for delivery and device research and development at Lilly, said: “Lilly is focused on delivering the broadest portfolio of diabetes treatments in the industry, including innovative delivery methods to advance the treatment of diabetes.

“Companion's smart pen and app represent innovation that could one day fill a gap for millions of people with diabetes.” 

Companion Medical said Lilly's investment, along with that from other investors, could potentially enable it to complete testing of its technology and submit it to the FDA for approval. 

For Lilly it continues its application of digital technologies, many of which have been made under its diabetes alliance with Boehringer Ingelheim.

These include a diabetes management game and an online behavioural change programme.

28th May 2015

From: Healthcare

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

Peter Jackson
Rethinking our approach to infectious disease preparedness
The importance of long-term strategic investment to prepare for the next threat that emerges...
New from the PhRMA: Diversity in clinical trials principles summarised
In November 2020, PhRMA announced the first-ever, industry-wide principles on clinical trial diversity. The principles were approved by the PhRMA Boards of Directors and will take effect in April 2021....
New from the FDA: Diversity in clinical trials guidance summarised
In November 2020, the FDA released guidance to enable greater diversity in clinical trials through changes to eligibility criteria, enrolment practices, and trial designs....

Infographics